SeaStar Medical, a medical technology company, has filed an amended annual report for the fiscal year ended December 31, 2023. The report includes a restatement of certain financial statements due to errors in previously issued financials. The restatement does not require recovery of incentive-based compensation. The company's shares and warrants are listed on The Nasdaq Stock Market LLC under the symbols ICU and ICUCW, respectively. SeaStar Medical's market value, based on the closing price of common stock on January 5, 2024, was $24,232,239, with 74,419,458 shares outstanding as of April 26, 2024. The company has made several amendments to its original Form 10-K, including updates to the number of outstanding shares and corrections to the text of certifications. No financial statements were included in this...Show More

SeaStar Medical, a medical technology company, has filed an amended annual report for the fiscal year ended December 31, 2023. The report includes a restatement of certain financial statements due to errors in previously issued financials. The restatement does not require recovery of incentive-based compensation. The company's shares and warrants are listed on The Nasdaq Stock Market LLC under the symbols ICU and ICUCW, respectively. SeaStar Medical's market value, based on the closing price of common stock on January 5, 2024, was $24,232,239, with 74,419,458 shares outstanding as of April 26, 2024. The company has made several amendments to its original Form 10-K, including updates to the number of outstanding shares and corrections to the text of certifications. No financial statements were included in this amendment, and it does not contain or amend any disclosure with respect to internal control over financial reporting. The company's board is composed of seven members, with a staggered three-year term structure. The board has determined that six directors are independent under Nasdaq listing standards. SeaStar Medical's executive officers and directors have entered into various agreements, including a convertible note financing agreement with the Dow Pension Funds and a PIPE investment agreement. The company has also adopted a related person transaction policy and has arrangements for indemnification of directors and officers.